DRUG STUDY

Date Generic Brand Classificat Indication Mechanism Dosage & Time Adverse Nursing
Name Name ion of Action Frequency Given Reaction Consideration
03-24- Olanzapine Zyprexa Therapeut Psychotic Antagonize CNS: · Monitor and
21 ic: disorders: s dopamine NEUROLE report signs of
antipsych Acute and PTIC neuroleptic
otics, manic serotonin MALIGNAN malignant
mood episodes type 2 in T syndrome,
stabilizers
associate the CNS. SYNDROM including
d with Also has E, hyperthermia,
Pharmaco bipolar anticholiner SEIZURES diaphoresis,
logic: disorder gic, , agitation, generalized
thienoben (may be antihistami dizziness, muscle rigidity,
zodiazepi used with nic, and headache, altered mental
nes lithium or anti– restlessnes status,
valproate) alpha1- s, sedation, tachycardia,
, long- adrenergic weakness, changes in
term effects. dystonia, blood pressure
maintena Therapeuti insomnia, (BP), and
nce c Effects: mood incontinence.
therapy of Decreased changes, Symptoms
bipolar manifestati personality typically occur
disorder, ons of disorder, within 4–14
long-term psychoses. speech days after
treatment/ impairment, initiation of
maintena tardive drug therapy,
nce of dyskinesia. but can occur at
schizophr EENT: any time during
enia, amblyopia, drug use.
agitation rhinitis,
due to increased · Be alert for
schizophr salivation, new seizures or
enia or pharyngitis. increased
mania Resp: seizure activity,
(IM). cough, especially at
Unlabele dyspnea. the onset of
d Use: CV: drug treatment.
Managem orthostatic Document the
ent of hypotensio number,
anorexia n, duration, and
nervosa. tachycardia severity of
Treatment , chest seizures, and
of nausea pain. GI: report these
and constipatio findings to the
vomiting n, dry physician